Captopril inhibits the oxidative modification of apolipoprotein B-100 caused by myeloperoxydase in a comparative in vitro assay of angiotensin converting enzyme inhibitors. Eur. Pharmacol. 537: 31-6

P Van Antwerpen; I Legssyer; K Zouaoui Boudjeltia; S Babar; P Moreau; Nicole Moguilevsky; M Vanhaeverbeek; J Ducobu; J Nève

Captopril inhibits the oxidative modification of apolipoprotein B-100 caused by myeloperoxydase in a comparative in vitro assay of angiotensin converting enzyme inhibitors. Eur. Pharmacol. 537: 31-6

P Van Antwerpen, I Legssyer, K Zouaoui Boudjeltia, S Babar, P Moreau, Nicole Moguilevsky, M Vanhaeverbeek, J Ducobu, J Nève

Research output: Contribution to journal › Article

Original language	English
Pages (from-to)	31-36
Number of pages	6
Journal	European Journal of Pharmacology
Volume	537
Issue number	1-3
Publication status	Published - 2006

Cite this

Van Antwerpen, P., Legssyer, I., Zouaoui Boudjeltia, K., Babar, S., Moreau, P., Moguilevsky, N., Vanhaeverbeek, M., Ducobu, J., & Nève, J. (2006). Captopril inhibits the oxidative modification of apolipoprotein B-100 caused by myeloperoxydase in a comparative in vitro assay of angiotensin converting enzyme inhibitors. Eur. Pharmacol. 537: 31-6. European Journal of Pharmacology, 537(1-3), 31-36.

@article{6d82b633aecb449d8be3dfa112da4523,

title = "Captopril inhibits the oxidative modification of apolipoprotein B-100 caused by myeloperoxydase in a comparative in vitro assay of angiotensin converting enzyme inhibitors. Eur. Pharmacol. 537: 31-6",

author = "{Van Antwerpen}, P and I Legssyer and {Zouaoui Boudjeltia}, K and S Babar and P Moreau and Nicole Moguilevsky and M Vanhaeverbeek and J Ducobu and J N{\`e}ve",

year = "2006",

language = "English",

volume = "537",

pages = "31--36",

journal = "European Journal of Pharmacology",

publisher = "Elsevier",

number = "1-3",

}

Van Antwerpen, P, Legssyer, I, Zouaoui Boudjeltia, K, Babar, S, Moreau, P, Moguilevsky, N, Vanhaeverbeek, M, Ducobu, J & Nève, J 2006, 'Captopril inhibits the oxidative modification of apolipoprotein B-100 caused by myeloperoxydase in a comparative in vitro assay of angiotensin converting enzyme inhibitors. Eur. Pharmacol. 537: 31-6', European Journal of Pharmacology, vol. 537, no. 1-3, pp. 31-36.

Captopril inhibits the oxidative modification of apolipoprotein B-100 caused by myeloperoxydase in a comparative in vitro assay of angiotensin converting enzyme inhibitors. Eur. Pharmacol. 537: 31-6. / Van Antwerpen, P; Legssyer, I; Zouaoui Boudjeltia, K et al.
In: European Journal of Pharmacology, Vol. 537, No. 1-3, 2006, p. 31-36.

Research output: Contribution to journal › Article

TY - JOUR

T1 - Captopril inhibits the oxidative modification of apolipoprotein B-100 caused by myeloperoxydase in a comparative in vitro assay of angiotensin converting enzyme inhibitors. Eur. Pharmacol. 537: 31-6

AU - Van Antwerpen, P

AU - Legssyer, I

AU - Zouaoui Boudjeltia, K

AU - Babar, S

AU - Moreau, P

AU - Moguilevsky, Nicole

AU - Vanhaeverbeek, M

AU - Ducobu, J

AU - Nève, J

PY - 2006

Y1 - 2006

M3 - Article

VL - 537

SP - 31

EP - 36

JO - European Journal of Pharmacology

JF - European Journal of Pharmacology

IS - 1-3

ER -